Davita Inc.DVA

DaVita Inc. disclosed a negative shareholders’ equity of -$755.5 million in its 10-Q for the quarter ended 31 March 2026, even as cash and equivalents sat at $644.2 million and the company booked $3.42 billion in revenues. Net income attributable to the parent came in at $197.5 million, giving diluted EPS of $2.87 on 68.9 million diluted shares. Operating income clocked $481.9 million, while operating cash flow printed $320.8 million. The company used $102.0 million of that cash to buy property, plant and equipment-roughly the cost of a couple of dialysis clinics-while inventories of consumables fell by $20.3 million to $141.6 million.

What DaVita actually does is run dialysis centres and home-peritoneal programmes across the United States, with an emergency services line that fields patient calls 24/7. The company’s public materials showcase “Expanded Hemodialysis” and “Hemodiafiltration” as advances, but the clinical data cited stop short of claiming superiority over standard haemodialysis, calling the outcomes “comparable.” The balance sheet, meanwhile, is still the place where the polished story meets the unpolished numbers; the same 11-K that touts physician innovation also reports the negative equity, a tension the company has carried for years.

The company’s latest 10-Q shows total assets of $17.50 billion against liabilities of $16.45 billion, a gap that leaves shareholders’ equity at -$755.5 million. Revenue grew in the quarter, but the cash conversion and capital allocation choices matter more than the headline number. Inventory fell sequentially, which could reflect tighter supply or softer consumption; either way, it is not the stuff of investor decks. The diluted share count has been steady, but the management desks has authorised small insider sales in June, a gentle reminder that capital stories and capital stacks are not the same thing.

DaVita’s product pages and press materials are full of “advanced therapies,” “middle-molecule clearance,” and images of clinicians in scrubs, yet the clinical footnotes in those same pages emphasise “comparable outcomes” rather than breakthrough benefits. The contrast between the marketing slide and the balance-sheet footnote is the real story: the company’s operating engine is mature and cash-generative, but the capital structure still carries the weight of the past. The emergency dialysis line and peritoneal programme are real services, but they do not yet carry the revenue or margin profile to swing the ledger from red to black.

The company’s 11-K filing for 2025 also discloses that the DaVita 401(k) plan bought and sold DaVita shares during the year, a classic sign of internal capital management rather than external endorsement. The SEC EDGAR filings index for DaVita Inc. (CIK 927066) shows the full set of disclosures, including the 10-Q, 11-K, Form 4s and 144s that the source requires readers to read to see the gap between the polished story and the prosaic numbers.

The company’s own materials make clear that peritoneal dialysis is for medically qualified patients, with in-depth training required; the emergency line is for anyone needing support, regardless of provider. These are real products and real services, but they are not yet the drivers of structural margin improvement on the scale the marketing suggests. The innovation pages reference trials like MOTheR 8 and CONCORDIA 9, yet the outcomes described are “comparable,” a word that in clinical literature rarely moves share prices.

For now, DaVita’s cash generation is the story, not the equity story. The company’s operating cash flow of $320.8 million in the quarter is real, and the $644.2 million of cash on hand is real, but the negative equity is also real. The tension is not a glitch; it is the ledger’s way of saying the capital structure has not yet caught up with the operating engine. Investors who like the sector’s demographics may cheer the cash generation, while those who prefer clean balance sheets may wait for the equity line to turn positive.